Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Overview of attention for article published in Lancet Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 7 news outlets
blogs: 1 blog
twitter: 27 X users

patent: 2 patents
guideline: 3 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 32 X posts from 27 X users, with an upper bound of 212,831 followers.

Also in the Feb issue: Efficacy and safety of #erdafitinib in patients with locally advanced or metastatic #urothelialcarcinoma: long-term follow-up of a phase 2 study #gusm https://t.co/kulzqKAhR5

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study https://t.co/bKeNGVa1W7

RT @drenriquegrande: ⚡️ On @TheLancetOncol - Assessing the long-term efficacy and safety of of erdafitinib in patients with locally advanc…

RT @NatRevClinOncol: 24-months follow-up results of phase II BLC2001 study of the FGFRi erdafinitinib in pts with metastatic urothelial car…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 28 additional X posts.